BSE: 90 | NSE: 500488 | ISIN: INE358A01014
Market Cap: [Rs.Cr.] 5,526.91 | Face Value: [Rs.] 10
Industry: Pharmaceuticals - Multinational
TO THE MEMBERS
Your Directors have pleasure in presenting the Seventieth Annual Report and the AuditedAccounts of the Company for 15 months' period ended March 31, 2014.
(Rs. in Lakhs)
|For the period January 1, 2013 to March 31, 2014#||For year ended December 31, 2012|
|Profit Before Tax||294,55.35||214,99.29|
|Profit After Tax||198,45.07||144,70.05|
|Balance brought forward||418,20.25||329,95.61|
|Profit available for appropriation||616,65.32||474,65.66|
|Corporate Dividend Tax||8,58.51*||5,86.02|
|Transfer to Reserves||19,84.51||14,47.01|
|Balance carried forward||539,34.96||418,20.25|
* Includes Corporate Dividend Tax of Rs. 27.91 Lakhs for the year ended December 31,2012.
#The Company changed its accounting year from year ended December 31 to year endedMarch 31 effective this year. Accordingly, these financial statements are prepared for 15months' period from January 1, 2013 to March 31, 2014.
Your Directors recommend a dividend of Rs. 23/- per share on 2,12,49,302 fully paid-upEquity Shares of Rs. 10/- each of the Company for the period ended March 31, 2014. Theproposed dividend, if approved at the Annual General Meeting, will absorb a sum of Rs.48,87.34 Lakhs. (Previous year : Rs. 36,12.38 Lakhs) and Corporate Dividend Tax of Rs.8,30.60 Lakhs (Previous year : Rs. 5,86.02 Lakhs). The Corporate Dividend Tax is providedat the rate applicable on the day on which the Accounts were approved by the Board ofDirectors.
The total Reserves as on March 31, 2014 amounted to Rs. 766,60.20 Lakhs comprising ofAmalgamation Reserve Rs. 37.82 Lakhs, Capital Reserve Rs. 5,22.62 Lakhs, CapitalRedemption Reserve Rs. 2,52.48 Lakhs, General Reserve Rs. 219,12.32 Lakhs and Surplus asper the Statement of Profit & Loss amounting to Rs. 539,34.96 Lakhs.
directors' responsibility statement
Pursuant to Section 217 (2AA) of the Companies Act, 1956, your Directors state that :
1. In the preparation of the Accounts, the applicable accounting standards have beenfollowed.
2. They have selected such accounting policies and applied them consistently and madejudgments and estimates that are reasonable and prudent so as to give a true and fair viewof the state of affairs of the Company for the period ended March 31, 2014, and of theprofit of the Company for that period.
3. They have taken proper and sufficient care for the maintenance of adequateaccounting records in accordance with the provisions of the Companies Act, 1956 forsafeguarding the assets of the Company and for preventing and detecting fraud and otherirregularities.
4. They have prepared the accompanying Accounts for the period ended March 31, 2014, ona going concern basis.
No fixed deposits were accepted during the period.
information pursuant to section 217 of the companies act, 1956
The information required to be disclosed under Section 217(1)(e) of the Companies Act,1956 read with the Companies (Disclosure of Particulars in the Report of the Board ofDirectors) Rules, 1988 with respect to conservation of energy, technology absorption andforeign exchange earnings/outgo is given in Annexure I and forms part of this Report.
The information required under Section 217(2A) of the Companies Act, 1956, read withthe Companies (Particulars of Employees) Rules, 1975 is given in Annexure II and formspart of this Report. As per the provisions of Section 219(1)(b)(iv) of the Companies Act,1956, the Report and Accounts are being sent to the shareholders of the Company, excludingthe statement of particulars of employees under Section 217(2A) of the Companies Act,1956. Any shareholder interested in obtaining a copy of the said statement may write tothe Company at its Registered Office.
Mr Thomas Dee resigned as Director of the Company effective September 30, 2013.
Mr Ashok Dayal, who retires by rotation at the ensuing Annual General Meeting, does notseek re-appointment. The Board proposes not to fill up the vacancy, for the time being.
The Board places on record its sincere appreciation for the valuable support andguidence received from Mr Thomas Dee and Mr Ashok Dayal during their tenure.
Ms Valentine Yien was appointed as an Additional Director of the Company with effectfrom December 23, 2013, and holds office upto the date of the ensuing Annual GeneralMeeting. The Board recommends appointment of Ms Yien as Director of the Company, liable toretire by rotation.
Mr R. A. Shah and Mr Ranjan Kapur retire by rotation at the ensuing Annual GeneralMeeting and being eligible, offer themselves for re-appointment. The Board proposes toappoint them as Independent Directors, in terms of the provisions of Section 149 of theCompanies Act, 2013, for a term upto March 31, 2019, not liable to retire by rotation.
The Company has received declarations from Mr R. A. Shah and Mr Ranjan Kapur,confirming that they meet with the criteria of independence as prescribed undersub-section (6) of Section 149 of the Companies Act, 2013.
Your Directors have pleasure in recommending their appointment.
Deloitte Haskins & Sells LLP Chartered Accountants (ICAI Firm Registration No. :117366W), the Statutory Auditors, hold office upto the conclusion of the ensuing AnnualGeneral Meeting.
In view of completion of the term prescribed under the provisions of Section 139(2) ofthe Companies Act, 2013 for Deloitte Haskins & Sells LLF, the Statutory Auditors, yourBoard proposes rotation of the Auditors of the Company and recommend appointment of S R BC & CO LLFF Chartered Accountants (ICAI Firm Registration No. : 324982E) as theStatutory Auditors for a term of five years i.e. from financial year 2014-15 to financialyear 2018-19 and to hold office till the conclusion of the Seventy-fifth Annual GeneralMeeting of the Company (subject to ratification by Members at every Annual GeneralMeeting).
The Board places on record its sincere appreciation for the valuable services renderedby Deloitte Haskins & Sells LLP during its association with the Company over the past19 years.
M/s N I Mehta & Co., Cost Accountants (Registration No. 000023), having its officeat 115, Jolly Maker Chamber - II, Nariman Point, Mumbai - 400 021, are appointed as theCost Auditors of the Company for the financial year 2014-15 at a remuneration of Rs. 6.05Lakhs plus applicable taxes and reimbursement of out of pocket expenses.
The said remuneration will be subject to ratification by the shareholders at theensuing Annual General Meeting.
environment, health and safety
Compliance with relevant regulations coupled with effective management of these issuesis an integral part of the Company's operating philosophy and we stand committed tocontinually improve on these objectives. There was a considerable focus on improvingEnvironment, Health and Safety during the period under review by the Company.
The Company continuously endeavors to improve on environmental management to minimizethe adverse environmental impact and through all activities demonstrate commitment toprotecting the environment.
The Goa plant is a "ZERO" discharge plant. The Company has in place a modernstate of the art effluent treatment plant at the Goa unit, treating and dischargingwastewater with parameters of treated effluent well below the limits set by the localPollution Control Board. The treated water from waste water treatment plant is recycledfor horticulture within the site.
The rain water harvesting project, which was installed last year, resulted in 600 KL ofwater saving during monsoons. The emissions from boiler and generator stacks are monitoredregularly and are well below the limits set by the State Pollution Control Board. Theambient air quality is being monitored on a regular basis to conform to the compliance ofambient air quality standards. There is also a vermi-composting unit to convert canteenwaste into organic manure, which is used in the lawns and plantation inside the factorypremises. The plant's briquette (compressed groundnut shells, wastes from crops, etc.)fired boiler eliminates furnace oil usage. The annual CO2 emission reduction is740 tons and zero sulphur emissions.
The site has been awarded Zero Waste to Landfill certification in purview of wastedisposal. 81% of waste generated at the plant goes for recycling, 17% for incineration and2% for composting.
Environmental Key Performance Indicators are shared and discussed with the employees inorder to continuously minimise the impact on environment.
ii. health and Safety
The Company is committed to promoting health and safety of its employees. The Companyhas a dedicated Safety Officer and a Safety Committee in place, which includesrepresentation from workmen and meets regularly to review issues impacting plant safetyand employee health. Our EHS program includes the policy on Environment, Health andSafety, well defined EHS organizational structure, EHS Standard Operating Procedures andEHS specific programs.
Various key measures like conducting training programs on various health and safetyissues including dealing with epidemics, ergonomics, machine guarding, work safety, roadsafety, first-aid, manual handling, etc. have been implemented. Regular health checkup(once a year) of the plant employees is carried out. Detailed first-aid training bycertified agencies like Indian Red Cross Society has also been imparted to the employees.The plant celebrated National Safety Week from 4th to 10th of March, 2014. Variousactivities were planned during the week. Programs like safety quiz, drawing competition,slogan and hazard identification competition were conducted. Training programs by externalagencies were also conducted during the week, which included machine safety, guarding andmaterial handling from Green Triangle Society and first aid training from the Indian RedCross Society.
The plant also celebrated Road Safety Week in the month of January, 2014 in which roadsafety awareness programs were conducted. A two-wheeler conditioning camp was conductedfor employees at the site.
The plant has a well-equipped first aid room with a full-time nurse and OccupationalHealth Physician catering to employee needs.
The plant also has a full-fledged ambulance van.
A cross-functional team for Employee Health and Safety (EHS) and Emergency Action Plan(EAP) is in place.
Routine audits for Environment, Health and Safety compliance are conducted with theassistance of personnel from Abbott's global corporate team.
technology absorption and development
The R & D Centre of the Company at Goa is approved by the Department of Scientificand Industrial Research. It carries out development of new formulations and modificationof existing ones for life cycle management. The R & D Centre also carries outevaluation of product dossiers for introduction of new products through insourcing.Effective life cycle management, cost reduction in existing product and new vendordevelopment are focus areas at the R & D Centre.
The R & D Centre has played a key role in launching new products during the periodunder review e.g. Vertin OD Tablet (Vertigo), Dufaxamin tablet (Hepatic encephalopathy),Arachitol chewable tablets (Vitamin D3), Brufit tablet (Acute pain) and Titaferoninjection (Hepatitis C). It has also been instrumental in site to site technologytransfers for rationalization of production sites to improve efficiencies, costs and takecare of business exigencies; notable among them were technology transfer of Vertin andDuphaston to alternative manufacturing sites.
Your Board records its sincere appreciation for the significant contributions made byemployees across the Company through their continued commitment and dedication.
reports on corporate governance and management discussion and analysis
A Report on Corporate Governance along with a certificate from the Auditors of theCompany regarding compliance of the conditions of Corporate Governance as also aManagement Discussion and Analysis Report pursuant to Clause 49 of the Listing Agreementare annexed hereto.
|For and on behalf of the Board|
|Mumbai||R. A. Shah||Rehan A. Khan|
|May 28, 2014||Director||Managing Director|
Information pursuant to the Companies (Disclosure of Particulars in the Report of theBoard of Directors) Rules, 1988.
1. conservation of energy
(I) Energy conservation measures taken :
i. Installed briquette (solid biofuel) fired boiler as replacement of standby furnaceoil fired boiler, which will result in cost saving of approximately Rs. 13 Lakhs perannum. Boiler commissioned in February, 2014.
ii. Installed transparent glass view panel in place of aluminium louvers on side wallsof utility block, thereby overall 40% of existing louvers area is replaced by transparentglass. This has enabled illumination of the area inside the utility block through naturalsunlight thereby avoiding use of electrical light fixtures during daytime from 8 am to 5pm every day.
Estimated energy saving of approximately 5530 KWH (electrical units) per annum.
Installation completed in January 2014.
iii. Variable Frequency Drive installed for Bottle Decartoning Area Air Handling Unitin December, 2013 to eliminate throttling of dampers to regulate the flow to the area.This will result in electrical energy saving of approximately 6135 KWH per annum.
iv. Electricity source connection changed from Reliance Infra power to GovernmentElectricity Department power in May, 2013 to reduce the energy cost to the plant. Thiswill result in cost saving of approximately Rs. 1,80 Lakhs per annum.
(II) Additional investments and proposals, if any, being implemented for reduction inconsumption of energy :
i. Installation of Screw-type Air Compressor of 500 CFM capacity in place of existingReciprocating-type Air Compressor. Estimated Electrical Units saving of approximately40000 KWH per annum. Compressor commissioned in May, 2014.
ii. Variable Frequency Drive for Air handling Units for Facility Expansion Project.
iii. Variable Primary Circuit for chilled water system, which will reduce energy costof air conditioning system.
(iii) impact of the measures at (i) and (ii) above for reduction of energy consumptionand consequent impact on the cost of production of goods :
All above Energy and Cost savings benefitted the plant by more than Rs. 1,60 Lakhsduring the period under review.
(iv) Total energy consumption and energy consumption per unit of production :
|for the period January 1, 2013 to March 31, 2014||for year ended December 31, 2012|
|A. power & fuel consumption :|
|(i) Purchased (KWH Unit Millions)||4.88||3.11|
|Total amount (Rs. Lakhs)||3,77.87||4,62.90|
|(ii) Own Generation in KWH|
|through Diesel Generator||137,216||88,524|
|through Steam turbine/Generator||NA||NA|
|b) Biomass (Solid Biofuel)|
|Total amount (Rs. Lakhs)||57.75||5.20|
|Rate/ Kg (Rs.)||6.09||6.05|
|d) Furnace oil|
|Purchased (Kilo ltrs)||NIL||216.23|
|Total Amt (Rs. Lakhs)||NIL||1,02.60|
|Rate/ Ltr Rs.||NIL||47.45|
|e) Other/ Internal Generation||NA||NA|
B. consumption per Unit of products :
Since the Goa Plant manufactures different dosage forms, it is not practical toapportion utility cost based on available records.
2. technology absorption
A. Efforts made in Technology Absorption
Various new projects were undertaken at the Goa facility. Duphalac enema wascommercialised during the period, providing customers with a ready enema kit for use.Cremaffin and Cremaffin Plus primary packs were changed from glass bottle to PET bottles.This has resulted in reduction in waste, savings in transportation and reduction in noiselevels during manufacturing. Studies are under way to have Digene gel and Duphalac also inPET bottles.
B. Achievements of the Company's R & D Centre at Goa :
i. Development of new Pharmaceutical Products
ii. Establishing new technical capabilities
iii. Import substitutions and new vendor development
iv. Optimization, standardization and improvement of products and manufacturingprocesses
v. Technical evaluation of off the shelf products, to ensure quality and stability.
New formulations of Digene tablets and Digene gel were developed with improved flavourprofile and commercially launched as part of Digene promotion initiative. The R & Dcentre played a vital role in closely working with third party developers to launchproducts like Vertin OD (Vertigo), Dufaxamin (Hepatic encephalopathy), Arachitol chewabletablets (Vitamin D3) and Brufit OD (Acute pain).
A number of process improvement projects were undertaken and implemented. New processtrain for Digene gel manufacturing improved productivity. A number of new vendors of keyActive Pharmaceutical Ingredients and excipients were developed resulting in cost savingsof approximately Rs. 1,03 Lakhs, during the period under review.
C. Benefits derived as a result of the above R & D
A well-focused R & D effort has helped the Company in launching a number of newproducts in the Indian market. Life cycle management of key products have helped inrevitalising brands. Manufacturing process optimization helped to bring in improvedquality and efficiency. New vendor development of Active Pharmaceutical Ingredients andexcipients has helped to reduce cost, improve the efficiency of supply chain and toprevent product stock outs. Development of new products will strengthen the portfolio andadd to life cycle management in areas of Gastroenterology, Neuropsychiatry,Cardiometabolics and Women's Health.
D. Future plan of action
New product development and life cycle management continues to be a key deliverable ofthe team. Identifying opportunities for process improvements and cost rationalisation willalso be areas of focus. Opportunities to insource manufacturing and expand locallydeveloped products to other geographies are being identified. Variants of global productsmay be developed for improved therapeutic benefit of prevailing molecules. Innovativetechnologies may be explored for equally efficient, cost effective and quality products.
E. Expenditure on R & D
Rs. in Lakhs
|Total R & D expenditure as a percentage of total turnover||0.08%|
F. Technology absorption, adaptation and innovation
i. Efforts, in brief, made towards technology absorption, adaptation and innovation.
The Company interacts with Abbott Laboratories Intl. Co. USA, on an ongoing basis fortechnical expertise for products of high technology and pharmaceutical formulations.
ii. Benefits derived as a result of the above efforts, e.g., product improvement, costreduction, product development, import substitution, etc.
The Company has benefited as a result of the emphasis on innovation. Reduction in wastegeneration, energy consumption and improvement in product quality are some of the benefitsachieved in the current period.
iii. Imported technology (imported during the last five years reckoned from thebeginning of the financial period).
3. foreign exchange earnings and outgo
(I) Activities relating to exports; initiatives taken to increase exports; developmentof new export markets for products and services, and export plans.
The total foreign exchange earned during the period amounted to Rs. 23,96.78 Lakhs,which includes Rs. 14,10.24 Lakhs towards exports, Rs. 9,78.46 Lakhs towards amountrecovered from the affiliates and Rs. 8.08 Lakhs towards other earnings.
(II) Details of total foreign exchange used and earned.
Rs. in Lakhs
|A. Total foreign exchange used|
|(a) On import of raw materials, finished goods, consumable stores and capital goods||365,87.96|
|(b) On professional charges, sales promotion expenses, commission on export sales, registration fees, business travel, software, etc.||11,14.45|
|(c) On remittance during the period on account of dividend||27,08.79|
|B. Total foreign exchange earned||23,96.78|
For and on behalf of the Board
|Mumbai||R. A. Shah||Rehan A. Khan|
|May 28, 2014||Director||Managing Director|
|20-Aug-13||Abbott named Best Company to Work For in pharma sector|
|19-Jun-13||Abbott honored with Golden Peacock Global Business Excellence Award|
|12-Feb-13||Bhasker Iyer named Divisional VP, India for Abbotts Pharma unit|
|03-May-12||Abbott collaborates with Syngene to Open First Nutrition R&D Center in India|
|29-Feb-12||Abbott India recommends dividend|
|23-Sep-11||Abbott named Indias MNC Pharmaceutical Company of the Year award|
|30-Aug-14||GVK writes to civil aviation ministry for withdrawl of chairman nominee of BIAL|
|20-Nov-13||Sushant School, Deakin University partner for iDiDe|
|20-Nov-13||BSE, NSE to shift scrips to restricted group|
|20-Nov-13||DS Group accolades academic excellence|
|20-Nov-13||Pfizer board to consider Scheme of Amalgamation with Wyeth|
|20-Nov-13||Future Group in talks with Actis Capital to acquire Nilgiris|
Munir Shaikh , Chairman
Rajendra A Shah , Director
Ashok Dayal , Director
Ranjan Kapur , Director
Company Head Office / Quarters:
3-4 Corporate Park,
Sion Trombay Road Chembur,
Phone : Maharashtra-91-22-67978888 / Maharashtra-
Fax : Maharashtra-91-22-67978727/8920 / Maharashtra-
E-mail : email@example.com
Web : http://www.abbott.co.in
Sharepro Services India P Ltd
Samhita Complex,Plot No 13 AB,Saki Naka Andheri(E),Mumbai-400072
|Scheme Name||No. of Shares|
|Reliance Equity Opportunities Fund (G)||7,97,825|
|Reliance Pharma Fund (G)||4,24,845|
|Reliance Long-Term Equity Fund (G)||2,04,155|
|Reliance Tax Saver (ELSS) Fund - (G)||78,610|
|Reliance Close Ended Equity Fund - Sr A (G)||40,505|
Check whether Taxed / Tax free investment avenue is better for you
|Taxed Avenue||Tax-Free Avenue|
|Investment amount (Rs.)|
|Tenure of Investment (years)|
|Interest earned (% p.a)|
|Your tax bracket (%)|